AP31969
Phase 2Small molecule
AP31969 is one of 89 small molecule programs targeting Interaction. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
88
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
137 competitors in Atrial Fibrillation
#DrugCompanyPhaseTrials
1Calquence
AstraZenecaPreclinical
Rituxan
RochePreclinical
Coumadin
AAbbott
Preclinical
AP31969
AAcesion Pharma
Phase 2
Brukinsa
BBeOne Medicines
Preclinical
Imbruvica
PPharmacyclics LLC.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ondexxya
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Preclinical
Romazicon
CConrado Roberto Hoffmann Filho
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atrial Fibrillation1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AP31969. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAcesion Pharma